Leerink Partnrs Issues Optimistic Estimate for AUPH Earnings

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) – Analysts at Leerink Partnrs lifted their Q1 2026 earnings per share estimates for Aurinia Pharmaceuticals in a research note issued on Tuesday, November 4th. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will post earnings per share of $0.18 for the quarter, up from their prior estimate of $0.15. The consensus estimate for Aurinia Pharmaceuticals’ current full-year earnings is $0.11 per share. Leerink Partnrs also issued estimates for Aurinia Pharmaceuticals’ Q2 2026 earnings at $0.19 EPS, Q3 2026 earnings at $0.18 EPS, Q4 2026 earnings at $0.21 EPS, FY2026 earnings at $0.76 EPS and FY2027 earnings at $0.85 EPS.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.07. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The company had revenue of $73.47 million for the quarter, compared to analyst estimates of $67.70 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS.

Several other equities analysts have also weighed in on AUPH. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and set a $17.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Bloom Burton lowered shares of Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research note on Wednesday. Jefferies Financial Group raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the stock from $10.00 to $21.00 in a research report on Friday. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $15.00 target price (up from $9.00) on shares of Aurinia Pharmaceuticals in a report on Wednesday. Two research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $17.67.

Aurinia Pharmaceuticals Stock Up 4.7%

Shares of Aurinia Pharmaceuticals stock opened at $14.61 on Thursday. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of 33.98 and a beta of 1.30. The stock has a 50-day simple moving average of $12.28 and a 200-day simple moving average of $10.17. Aurinia Pharmaceuticals has a 52-week low of $6.55 and a 52-week high of $16.20. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Strs Ohio acquired a new position in shares of Aurinia Pharmaceuticals during the first quarter worth approximately $636,000. Hussman Strategic Advisors Inc. increased its position in Aurinia Pharmaceuticals by 70.0% during the second quarter. Hussman Strategic Advisors Inc. now owns 357,000 shares of the biotechnology company’s stock worth $3,024,000 after acquiring an additional 147,000 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in Aurinia Pharmaceuticals during the first quarter worth $86,000. Public Employees Retirement System of Ohio acquired a new position in Aurinia Pharmaceuticals during the 2nd quarter valued at $282,000. Finally, GAMMA Investing LLC boosted its holdings in Aurinia Pharmaceuticals by 56.1% in the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 1,744 shares during the period. 36.83% of the stock is currently owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.